Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: Results of a West Japan Oncology Group study

Isamu Okamoto, Kazuko Sakai, Satoshi Morita, Hiroshige Yoshioka, Hiroyasu Kaneda, Koji Takeda, Tomonori Hirashima, Yoshihito Kogure, Tatsuo Kimura, Toshiaki Takahashi, Shinji Atagi, Takashi Seto, Toshiyuki Sawa, Masashi Yamamoto, Miyako Satouchi, Motoyasu Okuno, Seisuke Nagase, Koichi Takayama, Keisuke Tomii, Tadashi MaedaSatoshi Oizumi, Shinji Fujii, Yusaku Akashi, Kazumi Nishino, Noriyuki Ebi, Kazuhiko Nakagawa, Yoichi Nakanishi, Kazuto Nishio

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Archival formalin-fixed, paraffin-embedded (FFPE) tumor specimens were collected from advanced NSCLC patients enrolled in LETS phase III trial comparing first-line S-1/carboplatin with paclitaxel/carboplatin and subjected to multiplex genotyping for 214 somatic hotspot mutations in 26 genes (LungCarta Panel) and 20 major variants of ALK, RET, and ROS1 fusion genes (LungFusion Panel) with the Sequenom MassARRAY platform. MET amplification was evaluated by fluorescence in situ hybridization. A somatic mutation in at least one gene was identified in 48% of non-squamous cell carcinoma and 45% of squamous cell carcinoma specimens, with EGFR (17%), TP53 (11%), STK11 (9.8%), MET (7.6%), and KRAS (6.2%). Mutations in EGFR or KRAS were associated with a longer or shorter median overall survival, respectively. The LungFusion Panel identified ALK fusions in six cases (2.5%), ROS1 fusions in five cases (2.1%), and a RET fusion in one case (0.4%), with these three types of rearrangement being mutually exclusive. Nine (3.9%) of 229 patients were found to be positive for de novo MET amplification. This first multiplex genotyping of NSCLC associated with a phase III trial shows that MassARRAY-based genetic testing for somatic mutations and fusion genes performs well with nucleic acid derived from FFPE specimens of NSCLC tissue.

Original languageEnglish
Pages (from-to)2293-2304
Number of pages12
JournalOncotarget
Volume5
Issue number8
DOIs
Publication statusPublished - Jan 1 2014

Fingerprint

Carboplatin
Paclitaxel
Non-Small Cell Lung Carcinoma
Japan
Mutation
Gene Fusion
Paraffin
Formaldehyde
Genetic Testing
Fluorescence In Situ Hybridization
Nucleic Acids
Genes
Squamous Cell Carcinoma
Survival
Tyr sulfate(1)-enkephalinamide-leu
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin : Results of a West Japan Oncology Group study. / Okamoto, Isamu; Sakai, Kazuko; Morita, Satoshi; Yoshioka, Hiroshige; Kaneda, Hiroyasu; Takeda, Koji; Hirashima, Tomonori; Kogure, Yoshihito; Kimura, Tatsuo; Takahashi, Toshiaki; Atagi, Shinji; Seto, Takashi; Sawa, Toshiyuki; Yamamoto, Masashi; Satouchi, Miyako; Okuno, Motoyasu; Nagase, Seisuke; Takayama, Koichi; Tomii, Keisuke; Maeda, Tadashi; Oizumi, Satoshi; Fujii, Shinji; Akashi, Yusaku; Nishino, Kazumi; Ebi, Noriyuki; Nakagawa, Kazuhiko; Nakanishi, Yoichi; Nishio, Kazuto.

In: Oncotarget, Vol. 5, No. 8, 01.01.2014, p. 2293-2304.

Research output: Contribution to journalArticle

Okamoto, I, Sakai, K, Morita, S, Yoshioka, H, Kaneda, H, Takeda, K, Hirashima, T, Kogure, Y, Kimura, T, Takahashi, T, Atagi, S, Seto, T, Sawa, T, Yamamoto, M, Satouchi, M, Okuno, M, Nagase, S, Takayama, K, Tomii, K, Maeda, T, Oizumi, S, Fujii, S, Akashi, Y, Nishino, K, Ebi, N, Nakagawa, K, Nakanishi, Y & Nishio, K 2014, 'Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: Results of a West Japan Oncology Group study', Oncotarget, vol. 5, no. 8, pp. 2293-2304. https://doi.org/10.18632/oncotarget.1906
Okamoto, Isamu ; Sakai, Kazuko ; Morita, Satoshi ; Yoshioka, Hiroshige ; Kaneda, Hiroyasu ; Takeda, Koji ; Hirashima, Tomonori ; Kogure, Yoshihito ; Kimura, Tatsuo ; Takahashi, Toshiaki ; Atagi, Shinji ; Seto, Takashi ; Sawa, Toshiyuki ; Yamamoto, Masashi ; Satouchi, Miyako ; Okuno, Motoyasu ; Nagase, Seisuke ; Takayama, Koichi ; Tomii, Keisuke ; Maeda, Tadashi ; Oizumi, Satoshi ; Fujii, Shinji ; Akashi, Yusaku ; Nishino, Kazumi ; Ebi, Noriyuki ; Nakagawa, Kazuhiko ; Nakanishi, Yoichi ; Nishio, Kazuto. / Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin : Results of a West Japan Oncology Group study. In: Oncotarget. 2014 ; Vol. 5, No. 8. pp. 2293-2304.
@article{3e24ae599d4541189f495643ad1c3765,
title = "Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: Results of a West Japan Oncology Group study",
abstract = "Archival formalin-fixed, paraffin-embedded (FFPE) tumor specimens were collected from advanced NSCLC patients enrolled in LETS phase III trial comparing first-line S-1/carboplatin with paclitaxel/carboplatin and subjected to multiplex genotyping for 214 somatic hotspot mutations in 26 genes (LungCarta Panel) and 20 major variants of ALK, RET, and ROS1 fusion genes (LungFusion Panel) with the Sequenom MassARRAY platform. MET amplification was evaluated by fluorescence in situ hybridization. A somatic mutation in at least one gene was identified in 48{\%} of non-squamous cell carcinoma and 45{\%} of squamous cell carcinoma specimens, with EGFR (17{\%}), TP53 (11{\%}), STK11 (9.8{\%}), MET (7.6{\%}), and KRAS (6.2{\%}). Mutations in EGFR or KRAS were associated with a longer or shorter median overall survival, respectively. The LungFusion Panel identified ALK fusions in six cases (2.5{\%}), ROS1 fusions in five cases (2.1{\%}), and a RET fusion in one case (0.4{\%}), with these three types of rearrangement being mutually exclusive. Nine (3.9{\%}) of 229 patients were found to be positive for de novo MET amplification. This first multiplex genotyping of NSCLC associated with a phase III trial shows that MassARRAY-based genetic testing for somatic mutations and fusion genes performs well with nucleic acid derived from FFPE specimens of NSCLC tissue.",
author = "Isamu Okamoto and Kazuko Sakai and Satoshi Morita and Hiroshige Yoshioka and Hiroyasu Kaneda and Koji Takeda and Tomonori Hirashima and Yoshihito Kogure and Tatsuo Kimura and Toshiaki Takahashi and Shinji Atagi and Takashi Seto and Toshiyuki Sawa and Masashi Yamamoto and Miyako Satouchi and Motoyasu Okuno and Seisuke Nagase and Koichi Takayama and Keisuke Tomii and Tadashi Maeda and Satoshi Oizumi and Shinji Fujii and Yusaku Akashi and Kazumi Nishino and Noriyuki Ebi and Kazuhiko Nakagawa and Yoichi Nakanishi and Kazuto Nishio",
year = "2014",
month = "1",
day = "1",
doi = "10.18632/oncotarget.1906",
language = "English",
volume = "5",
pages = "2293--2304",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "8",

}

TY - JOUR

T1 - Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin

T2 - Results of a West Japan Oncology Group study

AU - Okamoto, Isamu

AU - Sakai, Kazuko

AU - Morita, Satoshi

AU - Yoshioka, Hiroshige

AU - Kaneda, Hiroyasu

AU - Takeda, Koji

AU - Hirashima, Tomonori

AU - Kogure, Yoshihito

AU - Kimura, Tatsuo

AU - Takahashi, Toshiaki

AU - Atagi, Shinji

AU - Seto, Takashi

AU - Sawa, Toshiyuki

AU - Yamamoto, Masashi

AU - Satouchi, Miyako

AU - Okuno, Motoyasu

AU - Nagase, Seisuke

AU - Takayama, Koichi

AU - Tomii, Keisuke

AU - Maeda, Tadashi

AU - Oizumi, Satoshi

AU - Fujii, Shinji

AU - Akashi, Yusaku

AU - Nishino, Kazumi

AU - Ebi, Noriyuki

AU - Nakagawa, Kazuhiko

AU - Nakanishi, Yoichi

AU - Nishio, Kazuto

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Archival formalin-fixed, paraffin-embedded (FFPE) tumor specimens were collected from advanced NSCLC patients enrolled in LETS phase III trial comparing first-line S-1/carboplatin with paclitaxel/carboplatin and subjected to multiplex genotyping for 214 somatic hotspot mutations in 26 genes (LungCarta Panel) and 20 major variants of ALK, RET, and ROS1 fusion genes (LungFusion Panel) with the Sequenom MassARRAY platform. MET amplification was evaluated by fluorescence in situ hybridization. A somatic mutation in at least one gene was identified in 48% of non-squamous cell carcinoma and 45% of squamous cell carcinoma specimens, with EGFR (17%), TP53 (11%), STK11 (9.8%), MET (7.6%), and KRAS (6.2%). Mutations in EGFR or KRAS were associated with a longer or shorter median overall survival, respectively. The LungFusion Panel identified ALK fusions in six cases (2.5%), ROS1 fusions in five cases (2.1%), and a RET fusion in one case (0.4%), with these three types of rearrangement being mutually exclusive. Nine (3.9%) of 229 patients were found to be positive for de novo MET amplification. This first multiplex genotyping of NSCLC associated with a phase III trial shows that MassARRAY-based genetic testing for somatic mutations and fusion genes performs well with nucleic acid derived from FFPE specimens of NSCLC tissue.

AB - Archival formalin-fixed, paraffin-embedded (FFPE) tumor specimens were collected from advanced NSCLC patients enrolled in LETS phase III trial comparing first-line S-1/carboplatin with paclitaxel/carboplatin and subjected to multiplex genotyping for 214 somatic hotspot mutations in 26 genes (LungCarta Panel) and 20 major variants of ALK, RET, and ROS1 fusion genes (LungFusion Panel) with the Sequenom MassARRAY platform. MET amplification was evaluated by fluorescence in situ hybridization. A somatic mutation in at least one gene was identified in 48% of non-squamous cell carcinoma and 45% of squamous cell carcinoma specimens, with EGFR (17%), TP53 (11%), STK11 (9.8%), MET (7.6%), and KRAS (6.2%). Mutations in EGFR or KRAS were associated with a longer or shorter median overall survival, respectively. The LungFusion Panel identified ALK fusions in six cases (2.5%), ROS1 fusions in five cases (2.1%), and a RET fusion in one case (0.4%), with these three types of rearrangement being mutually exclusive. Nine (3.9%) of 229 patients were found to be positive for de novo MET amplification. This first multiplex genotyping of NSCLC associated with a phase III trial shows that MassARRAY-based genetic testing for somatic mutations and fusion genes performs well with nucleic acid derived from FFPE specimens of NSCLC tissue.

UR - http://www.scopus.com/inward/record.url?scp=84899533736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899533736&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.1906

DO - 10.18632/oncotarget.1906

M3 - Article

C2 - 24810493

AN - SCOPUS:84899533736

VL - 5

SP - 2293

EP - 2304

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 8

ER -